CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

203284Orig1s000

CHEMISTRY REVIEW(S)



MEMORANDUM DEPATMENT OF HEALTH AND HUMAN SERVICES

PUBLIC HEALTH SERVICE

FOOD AND DRUG ADMINISTARTION

CENTER FOR DRUG EVALUATION AND RESEARCH

DATE: January 16, 2013

TO: NDA 203284 CMC Review # 1

FROM: Hamid R. Shafiei, Ph.D., CMC Reviewer

(ONDQA/Division II/Branch IV)

THROUGH: Moo-Jhong Rhee, Ph.D., Branch Chief

(ONDQA/Division II/Branch IV)

SUBJECT: Final CMC Recommendation

In review # 1 of NDA 203284 for Ravicti Liquid for oral use, this NDA was not recommended for approval from the CMC perspective due to the following reasons:

- 1) CMC related label/labeling issues were *not* resolved
- 2) An overall recommendation of "Acceptable" from the Office of Compliance regarding the facilities involved in this NDA was *not* yet issued

The CMC label/labeling issues have been resolved via the amendments dated December 13, 2012 and December 31, 2012 (see the **Attachment -2**).

The Office of Compliance has also made an overall recommendation of "Acceptable" for the facilities involved in this NDA on January 14, 2013 (see the **Attachment-1**).

Recommendation:

This NDA is now recommended for **approval** from the ONDQA perspective.



Appendix

Attachement-1

EES Report

FDA CDER EES ESTABLISHMENT EVALUATION REQUEST DETAIL REPORT

Action Goal:

Application: NDA 203284/000

 Stamp Date:
 23-DEC-2011
 District Goal:
 24-NOV-2012

Regulatory: 23-JAN-2013

Applicant: HYPERION THERAP INC Brand Name: Glycerol Phenylbutyrate (HPN-100)

601 GATEWAY BLVD STE 200 Estab. Name:

SOUTH SAN FRANCISCO, CA 94080 Generic Name: Glycerol Phenylbutyrate (HPN-100)

 Priority:
 1
 Product Number; Dosage Form; Ingredient; Strengths

 Org. Code:
 180
 001; LIQUID; GLYCEROL PHENYLBUTYRATE; 25ML 002; LIQUID; GLYCEROL PHENYLBUTYRATE; 120ML 003; LIQUID; GLYCEROL PHENYLBUTYRATE; 450ML

Application Comment:

 FDA Contacts:
 C. TRAN-ZWANETZ
 Project Manager
 (HFD-800)
 3017963877


 H. SHAFIEI
 Review Chemist
 3017962326

M. KOWBLANSKY Team Leader 3017961390

Overall Recommendation: ACCEPTABLE on 14-JAN-2013 by D. SMITH (HFD-323) 3017965321

 PENDING
 on 07-FEB-2012
 by EES_PROD

 PENDING
 on 07-FEB-2012
 by EES_PROD



FDA Confidential - Internal Distribution Only

Page 1 of 8



FDA CDER EES ESTABLISHMENT EVALUATION REQUEST **DETAIL REPORT**

Establishment:	CFN:		FEI:	(b) (4)			
				(b) (4)			
DMF No:			AADA:				
Responsibilities:	DRUG SUB	STANCE OTHER TES	STER				
Establishment							
Comment: Profile:	CONTROL	TESTING LABORATORY		OA			
and the second		Tracket of the same			L		
Milestone Name Comment		Milestone Date	Request Type	Planned Completion	Decision	Creator	_
SUBMITTED TO OC		(b) (4)		<u></u>	Reason	d)	o) (4
SUBMITTED TO DO			GMP Inspection				
ASSIGNED INSPECTI	ION TO IB		GMP Inspection				
NODESTION DEDES	DUED		DESIGNATION OF STREET,	(b) (4)			
INSPECTION PERFO							
accordance with a Branch 2) for a PE testing of the non- application (NDA)	request from DUFA Pre-App sterile liquid (203284/000.	DFFI/IOB and CDER/ proval Inspection of the drug substance Glycero	OC/DIDQ/ICB2 (Into laboratory to evalu of Phenylbutyrate (G is Hyperion Therap	peutics, Inc., South San			
Manufacturing Ins		Coverage for this inspe CP 7346.832, Pre-App		ed under CP 7356.002, Dr	ug		
		obiological control test		conducted (b) (4 was a PAI covering the)		
finished dosage st			in in inspection	(b) (4)			
Laboratory system	ns. Profile clas	coverage of the labora ss CTL (Control Testin d that three lots of GPI	g Laboratory) was c	lities & Equipment, and covered during the			
DO RECOMMENDATI	ON	(b) (4)			ACCEPTABLE	(b) (4)	
					INSPECTION		
OC RECOMMENDATI	ON	(b) (4)			ACCEPTABLE	(b) (4)	
					DISTRICT RECON	MENDATION	

January 16, 2013 12:44 PM

FDA Confidential - Internal Distribution Only


Page 2 of 8



Addendum to CMC Review # 1 of NDA 203284

FDA CDER EES ESTABLISHMENT EVALUATION REQUEST DETAIL REPORT

Establishment:	CFN: (b) (4)	FEI: (b) (4)			
		(b) (4)			
DMF No:		AADA:			
Responsibilities:	DRUG SUBSTANCE MANUFACTURER				
	DRUG SUBSTANCE PACKAGER				
	DRUG SUBSTANCE RELEASE TESTER				
Establishment Comment:	PROVIDES FOR MANUFACTURING, QA PHENYLBUTYRATE, DSM)	/QC TESTING AND	RELEASE, PACKAGING, S	TABILITY TESTING (GL	YCEROL
					(b) (4)
Profile:	NON-STERILE API BY CHEMICAL SYNT	HESIS	OAI Status:	NONE	



January 16, 2013 12:44 PM

FDA Confidential - Internal Distribution Only

Page 3 of 8



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

